Elevated symmetrical dimethylarginine (sdma) after Oclacitinib (Apoquel) in dogs
127 reports to the FDA describe elevated symmetrical dimethylarginine (sdma) in dogs given Oclacitinib. That is 0.4% of all reports for this medicine, compared with 0.1% across reports for all dog medicines, so it is reported unusually often with this medicine.
127Reports
50%Marked serious
2.4%Recovered
13%Died or euthanised
60 daysTypical onset
Sponsored
How soon it started
How the animals did
Problems reported at the same time
Age of the animals
About this medicine
Oclacitinib controls itching from allergies (tablet, a JAK inhibitor).
Products with this ingredient include Apoquel. The FDA hides brand names in its public data, so these reports cover every product with the same active ingredients.
Questions owners ask
- Can Oclacitinib cause elevated symmetrical dimethylarginine (sdma) in dogs?
- 127 reports link the two, but a report alone does not prove the medicine was the cause: other illnesses, other medicines or coincidence can be involved. Your vet can judge it for your animal.
- How soon after a dose was it reported?
- In half of the reports with dates, it started within 60 days of the first dose.
- What should I do?
- Don't give another dose until you've spoken to your vet, and keep the packaging so you can tell them the product and dose. Your vet can also report it to the FDA (or you can, through the manufacturer or FDA form 1932a).
Elevated symmetrical dimethylarginine (sdma) with similar medicines
- Elevated symmetrical dimethylarginine (sdma) after Ilunocitinib (Zenrelia) 27 reports · 1.2% of its reports
All reported side effects of Oclacitinib in dogs · Medicines most reported with elevated symmetrical dimethylarginine (sdma)